Vitiligo-like depigmentation after pembrolizumab treatment in patients with non-small cell lung cancer: a case report

Immune checkpoint inhibitors (ICIs) targeting programmed death-1 (PD-1) pathway have significantly improved outcomes for patients with a variety of malignancies, including non-small cell lung cancer (NSCLC). In contrast, the incidence of immune-related cutaneous adverse events such as vitiligo have...

Descripción completa

Detalles Bibliográficos
Autores principales: Yun, Sook Jung, Oh, In-Jae, Park, Cheol Kyu, Kim, Young-Chul, Kim, Hyeon Bin, Kim, Hee-Kyung, Hong, A. Ram, Kim, In-Young, Ahn, Sung-Ja, Na, Kook-Joo, Choi, Yoo-Duk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481606/
https://www.ncbi.nlm.nih.gov/pubmed/32953529
http://dx.doi.org/10.21037/tlcr-20-386

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481606/
https://www.ncbi.nlm.nih.gov/pubmed/32953529
http://dx.doi.org/10.21037/tlcr-20-386

Ejemplares similares